Global Acquired Orphan Blood Disease Market

Report ID : 1456 | Published : 2022-11-22 | Pages: | Format: PDF/EXCEL

The market size of the Global Acquired Orphan Blood Disease Market in the year 2021 is valued at 7.35 billion and is predicted to reach 19.96 billion by the year 2030 at an 9.91% CAGR during the forecast period.

Insufficient red blood cells in the circulation results in acquired orphan blood disease, a rare type of rare blood illness. The inability of the body to manufacture red blood cells is a defining feature of this illness. Additionally, poor bone marrow function lowers the number of platelets by reducing the number of red blood cells in the blood. This drop in platelet count brings on anemia and thrombosis. Less red blood cells are present in anemia, a blood disorder. The most frequent cause of anemia is blood loss, which also has chronic effects. Globally increasing rates of chronic sickness will likely raise the demand for effective healthcare treatments and provide new market opportunities for acquired orphan blood diseases. People's increased awareness of healthcare-related issues in recent years is also anticipated to increase demand in the global market. The medical industry's improved technological advancements also foster new market expansion chances. Developing country citizens currently earn significantly more per capita, which enhances their capacity to invest more money in advanced healthcare choices. The contributing element will likely increase the market for acquired orphan blood disorders.

Furthermore, it is anticipated that strict regulatory guidelines will limit market expansion chances in the coming years. It is also predicted that fewer investments by industry participants in these uncommon diseases will hinder market development drivers. Additionally, the market entry of new companies is anticipated to be hampered by the increasing number of consolidations.

Market Segmentation:

The acquired orphan blood disease market is segmented on the therapy, disease indication and distribution channel. Based on therapy, the market is segmented into recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, thrombopoietin receptor agonists and others. Based on disease indication, the acquired orphan blood disease market is segmented into acquired agranulocytosis, acquired hemophilia, acquired von Willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome and others. Based on distribution channel, the acquired orphan blood disease market is segmented into hospital pharmacies, retail pharmacies and others.

Based on disease indication, the acquired hemophilia segment is accounted as a major contributor to the acquired orphan blood disease market

Based on disease indication, the acquired orphan blood disease market is segmented into acquired agranulocytosis, acquired hemophilia, acquired von Willebrand syndrome, paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome and others. The acquired hemophilia category grabbed the highest revenue share, and it is anticipated that it will continue to hold that position during the anticipated time. Patients with acquired hemophilia (A.H.), a rare autoimmune illness characterized by bleeding without having a personal or family history of clotting or coagulation disorders, experience bleeding. When the body's immune system unintentionally targets healthy cells or tissue, autoimmune diseases result.

The hospital pharmacy segment witnessed growth at a rapid rate

Based on distribution channel, the acquired orphan blood disease market is segmented into hospital pharmacies, retail pharmacies and others. The hospital pharmacy category is anticipated to grow significantly over the forecast period due to the increased quantity of medications being given by trained healthcare professionals in the hospital. The rise is linked to SMA's high rate of hospitalization. Due to the significant risk of respiratory problems and scoliosis, hospitals treat most patients. Additionally, residents of emerging nations are already earning much more per capita, increasing their ability to invest more money in high-quality healthcare options and fueling the expansion of the hospital pharmacy market.

North America acquired orphan blood disease market holds a significant revenue share in the region.

North America's acquired orphan blood disease market is expected to register the highest market share in revenue shortly due to the region's rising rate of blood-related diseases. It is also anticipated that increased healthcare insurance alternatives and R&D spending, notably in the U.S., on innovative medications will impact the region's market expansion prospects. The market in North America is expected to grow at a significant rate in the years to come since sophisticated and organized healthcare solutions are readily available. Additionally, the Asia Pacific is anticipated to expand significantly over the forecast period due to the government's growing efforts for efficient healthcare facilities, and the construction of the healthcare infrastructure is responsible for the surge. The demand for regional goods and services is predicted to rise as patient populations rise.

Competitive Landscape

Some major key players in the acquired orphan blood disease market are Alexion Pharmaceuticals, Inc., Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline plc., Cyclacel Pharmaceuticals, Inc., Onconova Therapeutics, Inc., Incyte Corporation and CTI BioPharma Corp.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Acquired Orphan Blood Disease Market Snapshot

Chapter 4. Global Acquired Orphan Blood Disease Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Therapy Estimates & Trend Analysis

5.1. by Therapy & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Therapy:

5.2.1. Recombinant Factor

5.2.2. Immunoglobulin Infusion Therapy

5.2.3. Activated Prothrombin Complex Concentrate

5.2.4. Thrombopoietin Receptor Agonists

5.2.5. Others

Chapter 6. Market Segmentation 2: by Disease Indication Estimates & Trend Analysis

6.1. by Disease Indication & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Disease Indication:

6.2.1. Acquired Agranulocytosis

6.2.2. Acquired Hemophilia

6.2.3. Acquired Von Willebrand Syndrome

6.2.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)

6.2.5. Myelodysplastic Syndrome

6.2.6. Other

Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis

7.1. by Distribution Channel & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Distribution Channel:

7.2.1. Hospital Pharmacy

7.2.2. Retail Pharmacy

7.2.3. Others

Chapter 8. Acquired Orphan Blood Disease Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2022-2030

8.1.2. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2030

8.1.3. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2030

8.1.4. North America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2022-2030

8.2.2. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2030

8.2.3. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2030

8.2.4. Europe Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2022-2030

8.3.2. Asia Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2030

8.3.3. Asia-Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2030

8.3.4. Asia Pacific Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.4. Latin America

8.4.1. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2022-2030

8.4.2. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2030

8.4.3. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2030

8.4.4. Latin America Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2022-2030

8.5.2. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2030

8.5.3. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2022-2030

8.5.4. Middle East & Africa Acquired Orphan Blood Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Alexion Pharmaceuticals, Inc.

9.2.2. Amgen, Inc.

9.2.3. Celgene Corporation

9.2.4. Eli Lilly and Company

9.2.5. Sanofi S.A.

9.2.6. GlaxoSmithKline plc.

9.2.7. Cyclacel Pharmaceuticals, Inc.

9.2.8. Onconova Therapeutics, Inc.

9.2.9. Incyte Corporation

9.2.10. CTI BioPharma Corp.

9.2.11. Other Prominent Players

By Therapy-

  • Recombinant Factor
  • Immunoglobulin Infusion Therapy
  • Activated Prothrombin Complex Concentrate
  • Thrombopoietin Receptor Agonists
  • Others

By Disease Indication-

  • Acquired Agranulocytosis
  • Acquired Hemophilia
  • Acquired Von Willebrand Syndrome
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Myelodysplastic Syndrome
  • Other

By Distribution Channel-

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients